Compare ACHC & TECH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACHC | TECH |
|---|---|---|
| Founded | 2005 | 1976 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 11.2B |
| IPO Year | 2011 | 1995 |
| Metric | ACHC | TECH |
|---|---|---|
| Price | $29.58 | $72.14 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 11 |
| Target Price | $22.67 | ★ $71.82 |
| AVG Volume (30 Days) | 3.1M | ★ 4.0M |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 0.62% |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.05 | ★ 0.81 |
| Revenue | ★ $3,312,769,000.00 | $1,219,635,000.00 |
| Revenue This Year | $5.08 | $2.49 |
| Revenue Next Year | $5.98 | $6.40 |
| P/E Ratio | $561.80 | ★ $88.95 |
| Revenue Growth | 5.04 | ★ 5.23 |
| 52 Week Low | $11.43 | $43.20 |
| 52 Week High | $35.83 | $72.37 |
| Indicator | ACHC | TECH |
|---|---|---|
| Relative Strength Index (RSI) | 44.95 | 75.01 |
| Support Level | $22.32 | $70.49 |
| Resistance Level | $30.20 | N/A |
| Average True Range (ATR) | 1.95 | 0.35 |
| MACD | -0.87 | -0.62 |
| Stochastic Oscillator | 27.14 | 83.74 |
Acadia Healthcare Co Inc acquires and develops behavioral healthcare facilities. Its facilities and services are classified into the following categories: acute inpatient psychiatric facilities; specialty treatment facilities; CTCs; and residential treatment centers. In which Acute inpatient psychiatric facilities contribute the majority of revenue in the United States. The Company has one reportable segment, behavioral healthcare services. The behavioral healthcare services segment provides inpatient and outpatient behavioral healthcare services.
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.